ArticleJournal of patient experience2026
Development of a Patient Journey Map for Metabolic Dysfunction-Associated Steatohepatitis: A Comprehensive Assessment of the Patient Journey in North America.
Article in Journal of patient experience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient experience maps are valuable tools for raising awareness of the patient journey, identifying resource gaps, enhancing access to essential services, and ultimately improving patient outcomes. Here, we describe the development of a metabolic dysfunction-associated steatohepatitis (MASH) patient journey map and its refinement through collaboration with a group comprising eight patient advocates and one person living with MASH, collectively known as the MASH Patient Organizations Who Enable Results (POWER) Council. The patient journey map aimed to identify challenges and unmet needs for people with MASH and to understand the specific experiences of various patient subpopulations. We identified gaps in symptom management, patient-healthcare professional communication, timely diagnoses, access to care, coordination between specialists, and understanding of the impact of MASH on patients' and caregivers' daily lives. These gaps were further compounded in those with severe MASH, particularly Hispanic/Latino populations. These findings highlight the challenges and unmet needs faced by people living with MASH and their caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.